Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mirle Schemionek

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
American Journal of Blood Research|March 21, 2012
Mouse models as tools to understand and study BCR-ABL1 diseasesSteffen Koschmieder, Mirle Schemionek
Methods in Molecular Biology (Clifton, N.J.)|September 2, 2016
Tumor Suppressor Analysis in CMLOliver Herrmann, Mirle Schemionek
Applied and Environmental Microbiology|August 9, 2005
Expression of the psl operon in Pseudomonas aeruginosa PAO1 biofilms: PslA performs an essential function in biofilm formationJörg Overhage, Mirle Schemionek, Jeremy S Webb, et al.
Applied and Environmental Microbiology|April 7, 2006
PslD is a secreted protein required for biofilm formation by Pseudomonas aeruginosaAndrea Campisano, Christine Schroeder, Mirle Schemionek, et al.
Journal of Hematology & Oncology|May 15, 2016
Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretionLijuan Han, Claudia Schubert, Johanna Köhler, et al.
Hemasphere|June 12, 2023
Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic AnemiaMargherita Vieri, Benjamin Rolles, Maria Crocioni, et al.
BMC Cancer|July 5, 2022
Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNKAzam Salimi, Kema Marlen Schroeder, Mirle Schemionek-Reinders, et al.
Drug Delivery and Translational Research|January 2, 2023
A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myelomaJosbert Metselaar, Twan Lammers, Amelie Boquoi, et al.
Plos One|October 4, 2022
Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemiaSaskia Maletzke, Azam Salimi, Margherita Vieri, et al.
Molecular Carcinogenesis|November 7, 2019
LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophiliaGuangxin Ma, Deniz Gezer, Oliver Herrmann, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
American Journal of Blood Research|March 21, 2012
Mouse models as tools to understand and study BCR-ABL1 diseasesSteffen Koschmieder, Mirle Schemionek
Methods in Molecular Biology (Clifton, N.J.)|September 2, 2016
Tumor Suppressor Analysis in CMLOliver Herrmann, Mirle Schemionek
Applied and Environmental Microbiology|August 9, 2005
Expression of the psl operon in Pseudomonas aeruginosa PAO1 biofilms: PslA performs an essential function in biofilm formationJörg Overhage, Mirle Schemionek, Jeremy S Webb, et al.
Applied and Environmental Microbiology|April 7, 2006
PslD is a secreted protein required for biofilm formation by Pseudomonas aeruginosaAndrea Campisano, Christine Schroeder, Mirle Schemionek, et al.
Journal of Hematology & Oncology|May 15, 2016
Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretionLijuan Han, Claudia Schubert, Johanna Köhler, et al.
Hemasphere|June 12, 2023
Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic AnemiaMargherita Vieri, Benjamin Rolles, Maria Crocioni, et al.
BMC Cancer|July 5, 2022
Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNKAzam Salimi, Kema Marlen Schroeder, Mirle Schemionek-Reinders, et al.
Drug Delivery and Translational Research|January 2, 2023
A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myelomaJosbert Metselaar, Twan Lammers, Amelie Boquoi, et al.
Plos One|October 4, 2022
Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemiaSaskia Maletzke, Azam Salimi, Margherita Vieri, et al.
Molecular Carcinogenesis|November 7, 2019
LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophiliaGuangxin Ma, Deniz Gezer, Oliver Herrmann, et al.
Pageof 4